<DOC>
	<DOCNO>NCT00006451</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Randomized phase II/III trial determine effectiveness bone marrow transplantation treat patient leukemia .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare unrelated donor bone marrow transplantation use T-cell-depleted marrow versus unmodified marrow adult child leukemia . II . Evaluate 2-year leukemia-free survival , primary secondary graft failure , graft-versus-host disease , infection , relapse patient . III . Assess quality life associate T-cell-depleted versus unmodified , unrelated donor transplantation . OUTLINE : This randomize , multicenter study . Patients stratify center . Patients receive myeloablative therapy accord diagnosis : acute lymphocytic leukemia lymphoblastic lymphoma treat total body irradiation ( TBI ) , testicular chest wall boost appropriate , follow cyclophosphamide ( CTX ) ; patient undifferentiated biphenotypic leukemia acute chronic myelocytic leukemia treat CTX follow TBI . Patients randomly assign receive non-T-cell-depleted , unrelated marrow versus T-cell-depleted , unrelated marrow . The modified marrow deplete T-lymphocytes counterflow elutriation positively select CD34 cell . Graft-versus-host disease ( GVHD ) prophylaxis cyclosporine methotrexate give unmodified marrow group . Patients receive modify marrow give antithymocyte globulin ( methylprednisolone ) graft rejection prophylaxis transplantation cyclosporine methylprednisolone GVHD prophylaxis transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myelocytic leukemia without history myelodysplastic syndrome Not first complete remission ( i.e. , great 5 % blast marrow ) ( 8 ; 21 ) , ( 15 ; 17 ) , 16q abnormality unless failure firstline induction therapy Acute lymphocytic leukemia ( ALL ) one follow category : In second third complete remission ( CR ) Highrisk ALL first CR , high risk define : Hypodiploidy OR pseudodiploidy ( 9 ; 22 ) , ( 4 ; 11 ) , ( 8 ; 14 ) Failure achieve CR 4 week induction therapy Elevated WBC presentation , i.e . : Greater 100,000 patient age 6 12 month Greater 200,000 patient age 1 20 year Greater 20,000 patient age 21 44 year Chronic myelogenous leukemia blast crisis ( i.e. , great 30 % promyelocytes plus blast bone marrow ) Stage IV lymphoblastic lymphoma Undifferentiated biphenotypic leukemia Unrelated donor available Patients age 35 younger : HLAA , B serologic identity HLADRB1 identity highresolution DNA typing OR Single HLAA B serologic mismatch DRB1 identity highresolution DNA typing OR HLAA B serologic identity single DRB1 mismatch high low resolution DNA typing Patients age 36 44 : HLAA B serologic identity HLADRB1 identity highresolution DNA type The following exclude : Relapse 12 month discontinue therapy patient age 1 10 year second remission Active central nervous system leukemic skin involvement Requirement additional mediastinal irradiation PATIENT CHARACTERISTICS : Age : Under 46 Performance status : Karnofsky 70100 % Lansky 50100 % Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.5 mg/dL AST le 3 time normal Renal : Creatinine normal OR Creatinine clearance great 60 mL/min Cardiovascular : Asymptomatic OR Resting LVEF great 40 % improve exercise Pulmonary : Asymptomatic OR DLCO great 45 % predict ( correct hemoglobin ) Other : HIV negative No uncontrolled viral , bacterial , fungal infection Not pregnant nursing PRIOR CONCURRENT THERAPY : No prior bone marrow transplantation No prior radiotherapy precludes total body irradiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>